[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Gains But Lags Market: What You Should Know",
    "summary": "In the latest trading session, Amgen (AMGN) closed at $285.92, marking a +1.6% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=d15747fcf134e9511dd711b3eb198bbf2c4f3bbd65d91e5ee3691becfd2e7d72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744408814,
      "headline": "Amgen (AMGN) Gains But Lags Market: What You Should Know",
      "id": 133895976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "In the latest trading session, Amgen (AMGN) closed at $285.92, marking a +1.6% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=d15747fcf134e9511dd711b3eb198bbf2c4f3bbd65d91e5ee3691becfd2e7d72"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise in Late Afternoon Trading",
    "summary": "Health care stocks advanced late Friday afternoon with the NYSE Health Care Index adding 1.8% and th",
    "url": "https://finnhub.io/api/news?id=1721f1fd5a4a6ce6d6def0cf22d44ecf998c7fbf2d6a5dabd7085905d48bdba6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744401561,
      "headline": "Sector Update: Health Care Stocks Rise in Late Afternoon Trading",
      "id": 133895977,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Health care stocks advanced late Friday afternoon with the NYSE Health Care Index adding 1.8% and th",
      "url": "https://finnhub.io/api/news?id=1721f1fd5a4a6ce6d6def0cf22d44ecf998c7fbf2d6a5dabd7085905d48bdba6"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Gain in Afternoon Trading",
    "summary": "Health care stocks advanced Friday afternoon, with the NYSE Health Care Index adding 1.9% and the He",
    "url": "https://finnhub.io/api/news?id=5e3e8ea735f66047b5eab92c9fae6cbbd2e6fb19c7d5b8ee3257e44ff753ff94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744395162,
      "headline": "Sector Update: Health Care Stocks Gain in Afternoon Trading",
      "id": 133880752,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Health care stocks advanced Friday afternoon, with the NYSE Health Care Index adding 1.9% and the He",
      "url": "https://finnhub.io/api/news?id=5e3e8ea735f66047b5eab92c9fae6cbbd2e6fb19c7d5b8ee3257e44ff753ff94"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (NasdaqGS:AMGN) Clinical Trial Success In SCLC Treatment With IMDELLTRA",
    "summary": "Amgen (NasdaqGS:AMGN) made considerable strides in its oncology portfolio, as evidenced by the successful interim results for its DeLLphi-304 trial assessing IMDELLTRA for small cell lung cancer. These product advancements likely buoyed the company's recent quarterly price increase of 7.31%. Moreover, broader market movements contributed to shifts in Amgen's stock. Notably, the volatile trading activity, which saw the Dow and other indexes rally, subdued inflation data, and mixed economic...",
    "url": "https://finnhub.io/api/news?id=8e9c6fd6e60571e3daefc8fbc08f1b31a5e63d775ab6653deafdfe193ec14d79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744391810,
      "headline": "Amgen (NasdaqGS:AMGN) Clinical Trial Success In SCLC Treatment With IMDELLTRA",
      "id": 133880753,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NasdaqGS:AMGN) made considerable strides in its oncology portfolio, as evidenced by the successful interim results for its DeLLphi-304 trial assessing IMDELLTRA for small cell lung cancer. These product advancements likely buoyed the company's recent quarterly price increase of 7.31%. Moreover, broader market movements contributed to shifts in Amgen's stock. Notably, the volatile trading activity, which saw the Dow and other indexes rally, subdued inflation data, and mixed economic...",
      "url": "https://finnhub.io/api/news?id=8e9c6fd6e60571e3daefc8fbc08f1b31a5e63d775ab6653deafdfe193ec14d79"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock rises Friday, still underperforms market",
    "summary": "Amgen Inc. stock rises Friday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=c59c0ad6633f582cc3ea0f3952393ab5858745c3ebe232c41ec9c54c3b39fdba",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744389240,
      "headline": "Amgen Inc. stock rises Friday, still underperforms market",
      "id": 133887561,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock rises Friday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=c59c0ad6633f582cc3ea0f3952393ab5858745c3ebe232c41ec9c54c3b39fdba"
    }
  },
  {
    "ts": null,
    "headline": "IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER",
    "summary": "Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis. IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care (SOC) chemotherapy.",
    "url": "https://finnhub.io/api/news?id=a2b53c7269d32b579f88946784ea100e73b39fb0a51ddaf7483d8fdd6ab0f9a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744376400,
      "headline": "IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER",
      "id": 133880754,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis. IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care (SOC) chemotherapy.",
      "url": "https://finnhub.io/api/news?id=a2b53c7269d32b579f88946784ea100e73b39fb0a51ddaf7483d8fdd6ab0f9a0"
    }
  },
  {
    "ts": null,
    "headline": "Warning For SCHD Investors: Tariffs Are A Major Risk",
    "summary": "The Schwab U.S. Dividend Equity ETF typically offers stability, yet global trade tensions could expose its vulnerabilities. Find out why SCHD is rated hold.",
    "url": "https://finnhub.io/api/news?id=ce64faef5d8491da1826cf994e1f689a332e53ea257d21af991eb4bc2a897c0c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744359300,
      "headline": "Warning For SCHD Investors: Tariffs Are A Major Risk",
      "id": 133878500,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/174676710/image_174676710.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "The Schwab U.S. Dividend Equity ETF typically offers stability, yet global trade tensions could expose its vulnerabilities. Find out why SCHD is rated hold.",
      "url": "https://finnhub.io/api/news?id=ce64faef5d8491da1826cf994e1f689a332e53ea257d21af991eb4bc2a897c0c"
    }
  },
  {
    "ts": null,
    "headline": "Pharma’s US manufacturing moment: Where companies are making the biggest moves",
    "summary": "The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.",
    "url": "https://finnhub.io/api/news?id=d17e0a6b405718246d3091f4b7ddba60090760d1e24f1b6cd1bb038889f5e884",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744355602,
      "headline": "Pharma’s US manufacturing moment: Where companies are making the biggest moves",
      "id": 133880595,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.",
      "url": "https://finnhub.io/api/news?id=d17e0a6b405718246d3091f4b7ddba60090760d1e24f1b6cd1bb038889f5e884"
    }
  },
  {
    "ts": null,
    "headline": "Aristotle Capital Value Equity Composite Q1 2025 Commentary",
    "summary": "For Q1 2025, Aristotle Capitalâs Value Equity Composite posted a total return of 0.78% (gross) and 0.73% (net). Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=e99f32dcd317d9687e0acd2a64f19d6bc41b4525b44bc8d00a4bde390e94cf58",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744337100,
      "headline": "Aristotle Capital Value Equity Composite Q1 2025 Commentary",
      "id": 133876371,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159126735/image_2159126735.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "For Q1 2025, Aristotle Capitalâs Value Equity Composite posted a total return of 0.78% (gross) and 0.73% (net). Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=e99f32dcd317d9687e0acd2a64f19d6bc41b4525b44bc8d00a4bde390e94cf58"
    }
  }
]